# Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer

> **NCT04009941** · PHASE4 · COMPLETED · sponsor: **Peking University** · enrollment: 104 (actual)

## Conditions studied

- Breast Cancer
- Neutropenia

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT04009941
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2020-01-18
- **Final completion:** 2020-01-31
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04009941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04009941, "Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04009941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*